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Background: Evidence on the biological behavior and clinical courses of minimally invasive and widely invasive
follicular thyroid carcinoma (MI-FTC, WI-FTC) is still debatable. The current study was conducted to identify differences
between MI and WI tumors and those prognostic parameters influencing late outcome such as local recurrence and
survival.
Methods: From January 1998 to October 2013, 71 patients were operated on in our department because of a FTC. A
retrospective cohort study was carried out to compare 42 MI-FTC and 29 WI-FTC. The comparison involved evaluation
of patient characteristics, tumor characteristics, tumor staging, and risk assessment.
Results: A diameter greater than 4.0 cm, the presence of vascular invasion, the TNM stage III–IVA, and the high risk at
AMES system risk stratification were independent factors significantly related to the presence of a WI-FTC. The
only independent predictor of recurrence and disease-free survival at 10-year follow-up was a tumor size
greater than 4.0 cm.
Conclusions: More attention must be paid in the postoperative tumor re-staging of those patients with tumor
size larger than 4.0 cm, which was the only parameter predicting recurrence and influencing disease-free survival.
Nevertheless, definitive recommendations cannot be made without a longer follow-up.
Keywords: Follicular thyroid carcinoma, Minimally invasive carcinoma, Widely invasive carcinoma, Lymph node
metastasis, Recurrence, PrognosisBackground
Follicular thyroid carcinoma (FTC) accounts for 10–20 %
of differentiated thyroid carcinomas (DTCs), and it is the
second malignant tumor originating from the follicular cells
of the thyroid [1, 2]. In iodine-deficient areas, the relative
rate of FTC tends to be higher, up to 40 % of all cases of
DTC [3].
According to the World Health Organization (WHO)
classification of thyroid tumors, FTC is defined by the
presence of capsular and/or vascular invasion and by the
absence of nuclear features typical of papillary thyroid
carcinoma (PTC) [4]. FTC is more likely to metastasize
to distant organs rather than to regional lymph nodes* Correspondence: adolfo.pisanu@unica.it
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creativecommons.org/publicdomain/zero/1.0/because of its tendency to invade blood vessels thus
resulting in hematogenous dissemination [5].
WHO classification also divides FTC into minimally inva-
sive follicular thyroid carcinoma (MI-FTC) when limited
capsular and/or vascular invasion is found and widely inva-
sive follicular thyroid carcinoma (WI-FTC) in the case of
widespread infiltration of thyroid tissue and/or vascular in-
vasion [4]. Several authors usually reported a benign clinical
course of MI-FTC owing to the low risk of tumor recur-
rence and distant dissemination [1, 6–10]. Conversely,
other authors described that also MI-FTCs can give rise to
distant metastases [11].
WI-FTC is deemed to have a worse prognosis than
MI-FTC [12, 13]. The subset of prognostic factors asso-
ciated with WI-FTC, however, has not been deeply in-
vestigated yet [2].ticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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still a matter to be debated as some authors further subdi-
vided MI-FTCs into angioinvasive and non-angioinvasive
tumors [11, 14].
Age older than 45, sex, extrathyroid invasion, greater
tumor size, and the presence of distant metastasis at pres-
entation are recognized risk factors for poorer prognosis
of FTC [5, 12, 15, 16]. Nevertheless, there is controversy
concerning the prognostic significance of these risk fac-
tors, which could influence the treatment decision-making
of patients with FTC [11].
As evidence on the biological behavior and clinical
courses of MI-FTC and WI-FTC is still debatable, we
carried out a retrospective cohort study in order to iden-
tify differences between MI and WI tumors and those
prognostic parameters influencing late outcome such as
recurrence and distant metastases. The current research
was based on a single-institution experience, with homo-
geneity in the clinical management of patients with FTC.
Methods
From January 1998 to October 2013, 556 consecutive
patients were operated on in our surgical department
because of a DTC. Among them, 71 (12.7 %) were pa-
tients with FTC and they represented the cohort of pa-
tients for the current study.
FTC was defined in accordance with the 2004 WHO
classification of thyroid tumors as an invasive neoplasm
of follicular cell origin without the typical nuclear fea-
tures of PTC. Tumors were divided into MI-FTC when
limited capsular and/or vascular invasion was found and
WI-FTC in the case of widespread infiltration of thyroid
tissue and/or blood vessels [4]. Tumors with ≤3 foci of
vascular invasion were classified as MI-FTCs, whilst tu-
mors with >3 foci of vascular invasion were classified as
WI-FTCs. Hürthle cell thyroid tumors were excluded
from the study as we consider oncocytic cell tumor as a
distinctive clinical entity [17]. The follicular variant of
papillary thyroid cancer was also excluded.
All patients underwent ultrasonography of both thy-
roid and neck before operation. Those patients with sus-
pect of lymph node involvement by the tumor at
ultrasonography underwent magnetic resonance imaging
(MRI) of the neck and mediastinum.
Fine-needle aspiration cytology (FNAC) samples of the
thyroid nodules were obtained under ultrasonographic
guidance. Thyroid nodules showing cytological microfol-
licular features with severe atypia were considered as
highly suspicious of FTC. The diagnostic categories of
cytology were those of the British Thyroid Association
(Thy 1, non-diagnostic; Thy 2, benign, non-neoplastic;
Thy 3, follicular or suspected follicular or Hürthle neo-
plasm; Thy 4, suspicious of malignancy; Thy 5, diagnos-
tic of malignancy) [18]. Only a few patients underwentimmunocytochemical characterization of follicular nod-
ules by testing the expression of galectin-3 and HBME-1
in FNAC samples. Lateral lymph node involvement was
preoperatively assessed by means of both FNAC and/or
cytological detection of thyroglobulin in cervical lymph
nodes.
Intraoperative frozen section, when executed, was car-
ried out with at least four sections obtained from the
tumor. Thin anatomical slices (at least ten) were made
to carefully analyze thyroid nodule. Metastatic lymph
nodes were routinely examined with four histological
sections.
We carried out a retrospective cohort study in order
to compare 42 MI-FTC patients and 29 WI-FTC pa-
tients. The allocation of patients to the group MI or WI
was based on the pathological epicrisis. The current
study was conducted in accordance with the recommen-
dations from the Strengthening the Reporting of Obser-
vational Studies in Epidemiology (STROBE) guidelines
for reporting observational studies [19].
All the medical records were retrospectively reviewed.
The comparison involved evaluation of patient characteris-
tics (age and gender), tumor characteristics such as pre-
operative suspect of malignancy, tumor size, pathologic
association, multifocality, thyroid capsular invasion, vascu-
lar invasion, extrathyroid invasion, lymph node involvement
at presentation, the presence of a well/poorly differentiated
tumor, tumor staging, and risk assessment. Pathologic can-
cer staging was in accordance with the pTNM (pathologic
tumor node metastasis) system. Tumor risk was assessed
according to the most common risk group system such as
AMES (age, metastasis to distant sites, extrathyroidal inva-
sion and size) [20] and AJCC (American Joint Committee
on Cancer) pTNM staging following the 2010 pTNM-
AJCC system [15].
Indications for surgical treatment, management char-
acteristics, surgical complications such as inferior laryn-
geal nerve palsy and postoperative hypocalcemia, and
follow-up results were also evaluated. Postoperative
hypocalcemia was defined as a serum calcium level less
than 8.0 mg/dl; patients were considered as having per-
manent hypoparathyroidism and permanent inferior la-
ryngeal nerve palsy if the impaired function persisted
after 6 months from the operation [21].
After discharge, all patients entered a scheduled clinical
and instrumental follow-up program in the endocrino-
logical department on an average duration of 113.0 months
(range 12–288 months) and 125 months (range 24–196
months) in the MI and WI groups, respectively.
All patients diagnosed with a FTC underwent iodine-131
whole-body scan (WBS) 4–6 weeks after surgery, without
L-thyroxin treatment and when the TSH level was higher
than 30 μU/ml. A radioactive-iodine (RAI) ablating dose of
100 mCi (3700 MBq) was used to ablate microscopic
Table 1 Tumor characteristics
Characteristics MI-FTC WI-FTC p
N° 42 29 –
Suspect of malignancy
by cytology (pre-op)
30 (71.4 %)a 15 (51.7 %)b 0.133
Tumor size (mm), mean ± SD 27.05 ± 11.52 39.34 ± 15.44 0.000
Range 6–52 16–75
Median (95 % CI) 26 (23.57–30.53) 38 (33.72–44.96)
Tumor size ≤ 1.0 cm 4 (9.5 %) 0 0.140
Tumor size > 1.0 cm≤ 2.0 9 (21.4 %) 2 (6.8 %) 0.180
Tumor size > 2.0 cm≤ 4.0 25 (59.6 %) 15 (51.8 %) 0.628
Tumor size > 4 cm 4 (9.5 %) 12 (41.4 %) 0.003
Pathologic association
Multinodular goiter 13 (30.9 %) 10 (34.6 %) 0.800
Hashimoto’s thyroiditis 13 (30.9 %) 5 (17.2 %) 0.269
Graves’ disease 1 (2.4 %) 0 0.851
Normal thyroid 15 (35.8 %) 14 (48.2 %) 0.332
Follicular thyroid adenoma 1 (2.4 %) 0 0.851
Papillary microcarcinoma 6 (14.3 %) 3 (10.3 %) 0.729
Multifocality 0 2 (6.8 %) 0.163
Thyroid capsular invasion 0 1 (3.4 %) 0.408
Vascular invasion 9 (21.4 %) 15 (51.8 %) 0.011
Extra thyroid invasion 0 1 (3.4 %) 0.408
Lymph node metastasis 0 5 (17.2 %) 0.009
Well/Poorly differentiated 0 2 (6.8 %) 0.163
M1 at diagnosis 0 0 –
Concomitant parathyroid
cancer
1 (2.4 %) 0 0.851
MI-FTC minimally invasive - follicular thyroid carcinoma, WI-FTC widely invasive
- follicular thyroid carcinoma, SD standard deviation, CI confidence interval, M1
metastasis to distant sites
aMI-FTC: 28 Thy 3, 2 Thy 4
bWI-FTC: 13 Thy 3, 2 Thy 4
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WBS was done to search for missed metastases on the
previous WBS. L-thyroxin suppressive treatment was
started to maintain a serum TSH concentration of 0.1
μU/ml or less.
More recently, thyroglobulin (Tg) testing with human
recombinant thyrotropin (rhTSH-Thyrogen®) was evaluated
in a subgroup of patients prior to radioactive remnant abla-
tion. Patients received 0.9 mg by intramuscular injection on
days 1 and 2. Five mCi of iodine-131 were administered or-
ally on day 3, and a WBS was performed on day 5. Deter-
mination of serum FT3, FT4, Tg, anti-thyroglobulin
antibodies, and TSH were performed on day 1, prior to the
first rhTSH injection. Tg and TSH levels were reassessed
on days 3, 4, and 5.
Patients were followed-up at 6 and 12 months after treat-
ment and then on a yearly basis. Only patients with tumor
recurrence were resubmitted to RAI ablation therapy.
Patients with undetectable TSH-stimulated serum Tg levels,
without ultrasonographic evidence of neck lymph node me-
tastases and negative WBS, were defined as cancer-free.
Finally, 10-year overall and 10-year disease-free survivals
were evaluated in both groups. Written informed consent
was obtained from each patient to use data for scientific
purposes. The current research was approved and sup-
ported by the review board of our Institution and it was
conducted in accordance with the Declaration of Helsinki.
Statistical analysis and synthesis of the results
Data were collected in a planned relational computer
database (Microsoft Access®) including patients and
tumor characteristics. All statistical analyses were carried
out using the MedCalc® statistical software version
12.7.5 (MedCalc Software bvba, Ostend, Belgium; http://
www.medcalc.org; 2013).
Data for tumor size and postoperative hospital stay were
presented as the mean ± standard deviation (SD), as the
median value and 95 % confidence interval (CI). Data were
compared for statistical analysis using the Fisher exact test
to evaluate differences between qualitative variables and
using the Student’s t-test to compare quantitative variables.
The objective of statistical analysis was also to identify inde-
pendent risk factors significantly related to the presence of
a WI-FTC, to the recurrence of tumors, and to the disease-
free survival at 10-year follow-up by means of stepwise
logistic regression analysis. Differences were considered
significant when p < 0.05. P values of the study have been
reported as calculated by the statistical software.
Results
FTCs represented 12.7 % of all treated DTCs (71/556)
during the whole period of the study. MI-FTC group in-
cluded 36 women and 6 men (at a ratio of 6.0:1.0) with a
mean age of 45.74 years (range 20–78 years). WI-FTCgroup consisted of 26 women and 3 men (at a ratio of
8.6:1.0) with a mean age of 48.48 years (range 19–75
years). Age and gender were not significantly different
between groups. Moreover, the distribution of patients
over and under 45 was similar in both groups.
The comparative cohort study revealed that there was no
statistically significant difference regarding preoperative
cytological diagnosis between groups. As shown in Table 1,
30 patients (71.4 %) with MI-FC and 15 patients (51.7 %)
with WI-FTC were preoperative suspected as malignant by
cytology and for this reason, total thyroidectomy was per-
formed as a scheduled procedure. Altogether, the follicular
neoplasm of 26 patients was characterized by immunocyto-
chemical expression of galectin-3 and HBME-1 on FNAC
sample, without significant difference between MI-FTC and
WI-FTC (data not shown in tables). Five patients of the
WI-FTC group were diagnosed with cervical lymph node
Table 3 Operative technique and postoperative results
Parameter MI-FTC WI-FTC p
N° 42 29
TT 40 (95.2 %) 21 (72.6 %)
Completion thyroidectomy 2 (4.8 %) 3 (10.4 %)
TT + CND – 2 (6.8 %)
TT + CND +MRND ipsilateral – 1 (3.4 %)
TT + CND +MRND bilateral – 2 (6.8 %)
Frozen section (true positive) 2 (4.8 %) 0
Frozen section (false negative) 2 (4.8 %) 1 (3.4 %)
Mean postoperative hospital stay
(days) ± SD 3.7 ± 2.0 4.1 ± 2.5 0.520
Median (95 % CI) 3 (3.1–4.3) 3 (3.1–5.0)
Morbidity
Transient hypocalcaemia 6 (14.2 %) 4 (13.8 %) 0.773
Permanent hypocalcemia – –
Transient unilateral laryngeal
nerve palsy
– –
Permanent laryngeal nerve
palsy
– 1 (3.4 %) 0.851
I131 ablation therapy
0 application – – –
1 application 37 (88.1 %) 22 (76.0 %) 0.209
2 applications 5 (11.9 %) 4 (13.8 %) 0.898
4 applications – 1 (3.4 %) 0.064
5 applications – 1 (3.4 %)
8 applicationsa – 1 (3.4 %)
Tumor recurrence (node) – 3 (10.4 %) 0.064
Lateral neck compartment – 3 (10.4 %)
Central neck compartment – –
Loco-regional – 1 (3.4 %)
M1 at follow-up – 3 (10.4 %) 0.064
Overall recurrence rate – 7 (24.1 %) 0.001
Death of thyroid cancer – –
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vical lymph nodes was made in four patients, whilst high
levels of lymph node thyroglobulin were detected in one
patient (data not shown in tables).
Mean tumor size was significantly greater in the
WI-FTC group than in the MI-FTC group (39.34 vs.
27.05 mm, p = 0.000). Indeed, WI-FTCs were significantly
found with a diameter greater than 4.0 cm (p = 0.003)
when compared to MI-FTCs. There was no statistically
significant difference regarding pathologic thyroid associ-
ation. At univariate analysis, vascular invasion and lymph
node involvement at presentation were significantly
associated to the presence of a WI-FTC (p = 0.011 and
p = 0.009, respectively) (Table 1).
Higher cancer stage (III–IVA) was significantly related
to the presence of a WI-FTC (p = 0.006). High risk of
the AMES classification was significantly found in the
WI-FTC group (p = 0.023) (Table 2). Patients of both
groups were M0 at presentation.
Operative results, postoperative morbidity, and data
about postoperative ablation therapy with iodine-131
have been reported in details in Table 3. Five patients of
the WI-FTC group underwent total thyroidectomy asso-
ciated with neck lymphadenectomy, whilst no patients of
the MI-FTC group had more than total thyroidectomy.
There was no difference between groups about postoper-
ative hypocalcemia and postoperative laryngeal nerve
palsy. None of the patients of this cohort had permanent
hypoparathyroidism, and one patient of the WI-FTC
group had permanent inferior laryngeal nerve palsy.
After surgical treatment, all MI-FTC patients were
submitted to a standard dose of 100 mCi of RAI ablation
therapy. During follow-up, an additional dose of RAI
ablation therapy was administered in five patients
because of high thyroglobulin levels (>10 ng/ml) without
evidence of tumor recurrence. All WI-FTC patients were
submitted to a standard dose of 100 mCi of RAI ablation
therapy. During follow-up, an additional dose of RAI ab-
lation therapy was administered in one patient becauseTable 2 Tumor staging and risk assessment
Classification MI-FTC WI-FTC p
N° 42 29 –
pTNM - AJCC Staging 2010
I 23 (54.8 %) 11 (37.9 %) 0.024
II 13 (30.9 %) 4 (13.8 %) 0.156
III 6 (14.3 %) 13 (44.9 %) 0.006
IVA 0 1 (3.4 %) 0.408
AMES
Low risk 32 (76.2 %) 14 (48.2 %)
High risk 10 (23.8 %) 15 (51.8 %) 0.023
MI-FTC minimally invasive - follicular thyroid carcinoma, WI-FTC widely invasive
- follicular thyroid carcinoma
Death of other causes – –
Mean follow-up duration
(months) (range)
113 (12–288) 125 (24–196)
MI-FTC minimally invasive - follicular thyroid carcinoma, WI-FTC widely invasive
- follicular thyroid carcinoma, CND central neck dissection, MRND modified
radical neck dissection, SD standard deviation, CI confidence interval, M1
metastasis to distant site
aBone-marrow graft following aplastic anemia as side effect of multiple doses
of RAI ablation therapyof high thyroglobulin levels without evidence of tumor
recurrence; three patients had an additional dose of RAI
ablation after removal of nodal recurrence in the lateral
neck compartment (15, 24, and 25 months after the op-
eration, respectively); two patients had distant metastasis
at 12 and 36 months after surgery, and they underwent a
total of four and five doses of RAI ablation therapy,
Table 5 Independent risk factors for overall recurrence and
disease-free survival after stepwise logistic regression analysis
Parameter β SE χ2 p OR 95 % CI
Diameter >4 cm 1.909 0.967 3.903 0.048 6.750 1.01–44.92
β coefficient, SE standard error, χ2 chi square, OR odds ratio, CI
confidence interval
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node involvement had nodal and loco-regional recur-
rence 15 months after surgery and she was once more
submitted to a dose of 100 mCi of RAI ablation therapy.
Afterwards, she underwent a total of eight doses of RAI
ablation therapy for the occurrence of distant metasta-
ses. At 156 months from the first operation, she is alive
but she is not disease-free. Moreover, she was submitted
to a bone-marrow graft following an aplastic anemia as
side effect of multiple doses of RAI ablation therapy.
When analyzing seven patients with recurrence, three
of them underwent total thyroidectomy and neck
lymphadenectomy at first operation. In these patients,
recurrence was found in cervical nodes, which were sur-
gically removed before the second RAI ablation cycle.
One more patient, who previously underwent total thy-
roidectomy alone, had a cancer recurrence in the thyroid
bed and he was treated by only RAI ablation. Finally,
three patients with distant metastases were treated by
multiple doses of RAI ablation.
After a mean follow-up of 103.0 and 125.0 months in
the MI and WI group, respectively, none of the patients
in either group died because of FTC. Patients of the
MI-FTC group had 100 % overall and disease-free sur-
vival at 10 years. Patients of the WI-FTC group had
100 % overall survival and 75.8 % disease-free survival at
10 years, respectively.
Multivariate analysis showed that a diameter >4 cm,
the presence of vascular invasion, the TNM stage
III–IVA and the high risk of AMES system risk stratifi-
cation were independent prognostic factors significantly
related to the presence of a WI-FTC (Table 4).
Tumor size larger than 4.0 cm was the only factor
retained in the multivariate statistical model as inde-
pendent predictor of overall recurrence and influencing
disease-free survival (Table 5).
Discussion
Pathological diagnosis, treatment policy, and prognosis
of both MI-FTC and WI-FTC are still matters to be de-
bated. Recently, the review of the European Society of
Endocrine Surgeons has been published in an effort to
reach an evidence-based consensus on the managementTable 4 Prognostic factors significantly related to the presence
of a widely invasive FTC
Parameter β SE χ2 p OR 95 % CI
Diameter >4 cm 1.758 0.650 8.306 0.006 5.805 1.632-20.764
Vascular invasion 1.368 0.528 7.027 0.009 3.928 1.393-11.072
Stage III–IVA 1.722 0.576 9.807 0.002 5.600 1.808-17.340
AMES High Risk 1.232 0.519 5.848 0.017 3.428 1.239-9.481
Stepwise logistic regression analysis
β coefficient, SE standard error, χ2 chi square, OR odds ratio, CI confidence
interval, FTC follicular thyroid carcinomaof MI-FTC [22], whilst Ito et al. reported the clinical sig-
nificance of specific prognostic factors of WI-FTC [2].
Within this regard, the current study was carried out in
order to identify differences in clinical relevance between
MI and WI tumors.
The main results of the current investigation showed
that a diameter greater than 4.0 cm, the presence of vas-
cular invasion, the TNM stage III–IVA, and the high risk
at AMES system risk stratification were independent fac-
tors significantly related to the presence of a WI-FTC.
The only factor retained in the multivariate statistical
model as independent predictor of overall recurrence
and disease-free survival at 10-year follow-up was a
tumor size greater than 4.0 cm. Moreover, MI-FTC
group showed a median diameter of 2.6 cm vs. 3.8 cm of
the WI one and no patients of the MI group presented
with tumor recurrence at follow-up.
Our data confirm other studies in which WI-FTCs lar-
ger than 4.0 cm (T3 on TNM staging system) have a
worse prognosis because this diameter cut-off signifi-
cantly affects cancer recurrence and cancer-specific sur-
vival [1, 2, 23]. In the case of greater tumors with a
more likely aggressive biological behavior, a full treat-
ment protocol including total thyroidectomy, RAI abla-
tion, and L-thyroxin TSH-suppressive therapy and
careful follow-up are strongly recommended [2, 16, 22].
Multivariate analysis showed vascular invasion as inde-
pendently related to the presence of a WI-FTC. Indeed,
the presence of extensive vascular invasion has been re-
ported as associated with a higher risk of relapse in
WI-FTCs [22]. Some authors highlighted the importance
of vascular invasion in evaluating tumor prognosis by a
sub-classification of FTCs. D’Avanzo et al. identified a
group of MI-FTCs without vascular invasion (with 98 %
of disease-free survival at 10 years), an intermediate
MI-FTC group with vascular invasion and with or with-
out capsular invasion (with 80 % of disease-free survival
at 10 years), and a WI-FTC group (with 38 % of disease-
free survival at 10 years) [13]. Similarly, O’Neil et al.
showed that patients with MI-FTC without vascular in-
vasion had a better disease-free survival at 40 months
when compared with patients who had MI-FTC with
vascular invasion or WI-FTC (97, 81, and 46 %, respect-
ively) [6]. Several studies suggested that MI-FTC pa-
tients without vascular invasion could be treated by a
more conservative approach in term of thyroid lobec-
tomy [6, 7, 22, 24]. The choice of a less aggressive
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overall survival of patients with MI-FTC is essentially
identical to that of the general population [25].
Conversely, other studies reported the occurrence of
distant metastases also in MI-FTC patients without vas-
cular invasion [6, 11, 26]. This means that MI-FTC
could be a clinical dilemma being the most controversial
issue to deal with. For these reasons, some authors con-
sidered the currently accepted histological classification
of FTC as inadequate in predicting aggressive clinical
courses [11]. The unclear and sometime unpredictable
behaviors of MI-FTC persuaded these authors to recom-
mend total thyroidectomy and RAI ablation for all pa-
tients with FTC [3, 11]. Also in our experience, all
patients with MI-FTC were submitted to a full treatment
protocol without relapse at 10 year follow-up.
According to other authors, we applied a more aggres-
sive approach in all cases of FTC in terms of total thy-
roidectomy and RAI ablation therapy to facilitate the
oncologic follow-up as well as the detection of occult
metastases [3, 6, 11]. Our greatest concern was the pos-
sibility of overtreatment of patients belonging to the
MI-FTC group. However, in the absence of molecular
markers routinely used in predicting different biological
behavior of FTC, which is finally diagnosed postopera-
tively, changing our treatment approach may be difficult.
Moreover, frozen section examination of FTCs has
been proposed with the aim of modulating the treatment
policy of these neoplasms. Some authors supported the
use of frozen section in the management of FTCs be-
cause the diagnostic accuracy of malignancy was as high
as 78 % [27], whilst several authors did not find any add-
itional diagnostic value when using frozen section in the
management of FTCs [28, 29]. In our experience, we
performed only five intraoperative frozen sections
because three of them were diagnosed as false negative
requiring completion thyroidectomy.
Among several prognostic scoring systems, TNM sta-
ging is the most commonly used and it is considered as
a good system for evaluating FTC [9, 26, 30]. However,
the degree of invasiveness such as minimally invasive or
widely invasive tumor, which is the worldwide-accepted
classification of FTC, is not included in the TNM staging
system [10]. Further studies are needed to better assess
the impact of this discrepancy in the risk classification of
FTC. Moreover, the updated TNM staging system has
placed greater emphasis on the metastasis to lymph
nodes in predicting prognosis of DTC [15]. In the case
of FTC, there is a general agreement that nodal dissec-
tion must be performed only with therapeutic intent and
in the presence of clinical evidence for lymph node in-
volvement by the tumor [3, 17, 22]. In our practice, we
plan neck lymph node dissection only after a preopera-
tive detection of nodal involvement by the tumor (bynodal cytology or high nodal level of Tg). Indeed, when
no nodal metastases can be detected preoperatively,
there is no indication for prophylactic neck dissection in
FTCs [22, 31–33]. Moreover, a significant correlation
between tumor sizes of FTC greater than 4.0 cm and the
presence of nodal metastases at presentation was dem-
onstrated in previous studies [16, 33].
Conclusions
The greatest clinical relevance of WI-FTC has been
clearly showed by reviewing the literature and our own
experience. Within this regard, more attention must be
paid in the postoperative tumor re-staging of those
patients with tumor size larger than 4.0 cm, which was
the only parameter predicting overall recurrence and in-
fluencing disease-free survival. However, the unpredict-
able behaviors of MI-FTC and the need to facilitate the
oncologic follow-up persuaded us to recommend a full
treatment protocol for all patients with FTC.
An alternative, less aggressive operative strategy, per-
forming intraoperative frozen sections, did not achieve
any validation in our practice. Lymphadenectomy in
FTCs should be performed only after a preoperative de-
tection of nodal involvement by the tumor.
The good outcomes reported in the current study may
be related to our quite aggressive therapeutic strategy.
Nevertheless, definitive recommendations cannot be
made without a longer follow-up. Finally, the inclusion
of the degree of tumor invasiveness in the TNM staging
system must be taken into account.
Abbreviations
AMES: age, metastasis to distant sites, extrathyroidal invasion and size;
DTC: differentiated thyroid cancer; FNAC: fine-needle aspiration cytology;
FTC: follicular thyroid cancer; HBME-1: Hector Battifora mesothelial cell-1;
MI-FTC: minimally invasive - follicular thyroid cancer; MRI: magnetic
resonance; RAI: radioactive Iodine; Tg: thyroglobulin; TSH: Thyroid-stimulating
hormone; WBS: whole body scintigraphy; WI-FTC: widely invasive - follicular
thyroid cancer.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
PM did the conception and design, drafting the article, analysis and
interpretation of data, revising for intellectual content, approval of the final
version. SA did the acquisition of data and analysis, revising for intellectual
content, and approval of the final version. PF and RI did the analysis and
interpretation of data, revising for intellectual content, and approval of the
final version. PA did the conception and design, acquisition and
interpretation of data, drafting the article, revising for important intellectual
content, and approval of the final version. All authors read and approved the
final manuscript.
Acknowledgements
This study was supported by a grant from the University of Cagliari, Italy
(CAR 2013).
Received: 6 January 2015 Accepted: 22 May 2015
Podda et al. World Journal of Surgical Oncology  (2015) 13:193 Page 7 of 7References
1. Asari R, Koperek O, Scheuba C, Riss P, Kaserer K, Hoffmann M, et al. Follicular
thyroid carcinoma in an iodine-replete endemic goiter region: a prospective
collected, retrospectively analyzed clinical trial. Ann Surg. 2009;249:1023–31.
2. Ito Y, Hirokawa M, Masuoka H, Yabuta T, Fukushima M, Kihara M, et al.
Distant metastasis at diagnosis and large tumor size are significant
prognostic factors of widely invasive follicular thyroid carcinoma. Endocr J.
2013;60:829–33.
3. De Crea C, Raffaelli M, Sessa L, Ronti S, Fadda G, Bellantone C, et al. Actual
incidence and clinical behavior of follicular thyroid carcinoma: an
institutional experience. Sci World J. 2014. article ID 952095, http://
dx.doi.org/10.1155/2014/952095.
4. DeLellis RA, Lloyd RV, Heitz PU, et al. World Health Organization
classification of tumors: pathology and genetics of tumors of endocrine
organs. Lyon: IARC Press; 2004. p. 64–6. eds.
5. Kim HJ, Sung JY, Oh YL, Kim JH, Son YI, Min YK, et al. Association of vascular
invasion with increased mortality in patients with minimally invasive
follicular thyroid carcinoma but not widely invasive follicular thyroid
carcinoma. Head Neck. 2013. doi: 10.1002/hed.23511.
6. O’Neill CJ, Vaughan L, Learoyd DL, Sidhu SB, Delbridge LW, Sywak MS.
Management of follicular thyroid carcinoma should be individualized based
on degree of capsular and vascular invasion. Eur J Surg Oncol. 2011;37:181–5.
7. van Heerden JA, Hay ID, Goellner JR, Salomao D, Ebersold JR, Bergstralh EJ,
et al. Follicular thyroid carcinoma with capsular invasion alone: a non
threatening malignancy. Surgery. 1992;112:1130–6.
8. Huang CC, Hsueh C, Liu FH, Chao TZ, Lin JD. Diagnostic and therapeutic
strategies for minimally and widely invasive follicular thyroid carcinomas.
Surg Oncol. 2011;20:1–6.
9. Lo CY, Chan WF, Lam KY, Wam KY. Follicular thyroid carcinoma: the role of
histology and staging systems in predicting survival. Ann Surg.
2005;242:708–15.
10. Chow SM, Law SC, Mendenhall WM, Au SK, Yau S, Yuen KT, et al. Follicular
thyroid carcinoma: prognostic factors and the role of radioiodine. Cancer.
2002;95:488–98.
11. Ban EJ, Andrabi A, Grodski S, Yeung M, Mclean C, Serpell J. Follicular thyroid
cancer: minimally invasive tumors can give rise to metastases. ANZ J Surg.
2012;82:136–9.
12. Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Prognostic factors in papillary
and follicular thyroid carcinoma: their implication for cancer staging. Ann
Surg Oncol. 2007;14:730–8.
13. D’Avanzo A, Treseler P, Ituarte PH, Wong M, Streja L, Greenspan FS, et al.
Follicular thyroid carcinoma: histology and prognosis. Cancer.
2004;100:1123–9.
14. Collini P, Sampietro G, Pilotti S. Extensive vascular invasion is a marker of
risk of relapse in encapsulated non-Hürthle cell follicular carcinoma of the
thyroid gland: a clinicopathological study of 18 consecutive cases from a
single institution with a 11-year median follow up. Histopathology.
2004;44:35–9.
15. Edge SB, Byrd DR, Compton CC. AJCC Cancer Staging Manual, 7th edn, pp
87–96. New York: Springer; 2010.
16. Pisanu A, Deplano D, Pili M, Uccheddu A. Larger tumor size predicts nodal
involvement in patients with follicular thyroid carcinoma. Tumori.
2011;97:296–303.
17. Pisanu A, Di Chiara B, Reccia I, Uccheddu A. Oncocytic cell tumors of the
thyroid: factors predicting malignancy and influencing prognosis, treatment
decisions, and outcomes. World J Surg. 2010;34:836–43.
18. British Thyroid Association, Royal College of Physicians. British Thyroid
Association Guidelines for the management of thyroid cancer. 2. 2007.
http://www.british-thyroid-association.org/Guidelines/
19. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock
SJ, et al. Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE): explanation and elaboration. PLoS Med.
2007;4:e297. doi:10.1371/journal.pmed. 0040297.
20. Cady B, Rossi R, Silverman M, Wool M. Further evidence of the validity of
risk group definition in differentiated thyroid carcinoma. Surgery.
1985;98:1171–8.
21. Pisanu A, Reccia I, Nardello O, Uccheddu A. Risk factors for nodal metastasis
and recurrence among patients with papillary thyroid microcarcinoma:
differences in clinical relevance between nonincidental and incidental
tumors. World J Surg. 2009;33:460–8.22. Dionigi G, Kraimps J-L, Schmid KW, Hermann M, Sheu-Grabellus S-Y, De
Wailly P, et al. Minimally invasive follicular thyroid cancer (MIFTC)—a
consensus report of the European Society of Endocrine Surgeons (ESES).
Langenbecks Arch Surg. 2014;399:165–84.
23. Ito Y, Hirokawa M, Higashiyama T, Takamura Y, Miya A, Kobayashi K, et al.
Prognosis and prognostic factors of follicular carcinoma in Japan:
importance of postoperative pathological examination. World J Surg.
2007;31:1417–24.
24. Thompson LD, Wieneke JA, Pall E, Frommelt RA, Adair CF, Heffess CS. A
clinicopathologic study of minimally invasive follicular carcinoma of the
thyroid gland with a review of the English literature. Cancer. 2001;91:505–24.
25. Goffredo P, Cheung K, Roman SA, Sosa JA. Can minimally invasive follicular
thyroid carcinoma be approached as a benign lesion? A population-level
analysis of survival among 1.200 patients. Ann Surg Oncol. 2013;20:767–72.
26. Sugino K, Kameyama K, Ito K, Nagahama M, Kitagawa W, Shibuya H, et al.
Outcomes and prognostic factors of 251 patients with minimally invasive
follicular thyroid carcinoma. Thyroid. 2012;22:798–804.
27. Paphavasit A, Thompson GB, Hay ID, Grant CS, van Heerden JA, Ilstrup DM,
et al. Follicular and Hürthle cell thyroid neoplasms: is frozen-section evaluation
worthwhile? Arch Surg. 1997;132:674–80.
28. Udelsman R, Westra WH, Donovan PI, Sohn TA, Cameron JL. Randomized
prospective evaluation of frozen section analysis for follicular neoplasms of
the thyroid. Ann Surg. 2001;233:716–22.
29. Bronner MP, Hamilton R, LiVolsi VA. Utility of frozen section on follicular
lesions of the thyroid. Endocrinol Pathol. 1994;5:154–61.
30. Rios A, Rodriguez JM, Ferri B, Martinez-Barba E, Febrero B, Parrilla P. Are
prognostic scoring systems of value in patients with follicular thyroid
carcinoma? Eur J Endocrinol. 2013;169:821–7.
31. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al.
American Thyroid Association Guidelines Taskforce: Management guidelines
for patient with thyroid nodules and differentiated thyroid cancer. Thyroid.
2006;16:109–41.
32. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European
Thyroid Cancer Taskforce: European consensus for the management of
patients with differentiated thyroid carcinoma of the follicular epithelium.
Eur J Endocrinol. 2006;154:787–803.
33. Alfalah H, Cranshaw I, Jany T, Arnalsteen L, Leteurtre E, Cardot C, et al. Risk
factors for lateral cervical lymph node involvement in follicular thyroid
carcinoma. World J Surg. 2008;32:2623–6.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
